Stock Events

Stock Events

Soligenix

$0.000000

91

+$0.00+0% Friday 22:07

Statistics

Day High

-

Day Low

-

52W High

0.056

52W Low

0.056

Volume

-

Avg. Volume

0

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

31MarExpected

Q3 2024

Q1 2025

Q2 2025

Q3 2025

Q4 2025

-1.39

-1.11

-0.83

-0.56

Expected EPS

-0.56

Actual EPS

N/A

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Incyte Corporation operates in the same biopharmaceutical sector focusing on innovative therapies, directly competing in areas of immunology and oncology similar to Soligenix's pipeline.

Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that develops and markets drugs in areas overlapping with Soligenix's focus, including treatments for infectious diseases, potentially competing in the development of treatments for conditions like COVID-19.

Amgen Inc. competes in the biotech space, focusing on innovative human therapeutics. Their work in immune-oncology and inflammatory diseases competes with Soligenix's research and product development.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is known for its innovation in biopharmaceuticals, directly competing with Soligenix in the development of treatments for rare diseases and conditions requiring novel therapeutic approaches.

Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated operates in the biotechnology industry, focusing on creating new possibilities in medicine. Their work on cystic fibrosis and other serious diseases competes with Soligenix's efforts in rare diseases.

Biogen Inc. focuses on neurology, autoimmune and rare diseases, areas that overlap with Soligenix's therapeutic development, making them a competitor in the biopharmaceutical market.

Novo Nordisk A/S is a global healthcare company with a strong focus on diabetes care and other serious chronic conditions, potentially competing with Soligenix in the broader healthcare market.

Pfizer Inc. is a global biopharmaceutical company with a wide range of products in various therapeutic areas, including those that compete with Soligenix's focus areas.

Merck & Co., Inc. operates globally in pharmaceuticals, offering products that directly compete with Soligenix's in areas like oncology and infectious diseases.

Johnson & Johnson

Johnson & Johnson is a broad healthcare company that, through its pharmaceutical division, competes with Soligenix in developing treatments for a wide range of diseases, including areas of focus for Soligenix.

About

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

Show more...

CEO

Christopher J. Schaber

Employees

14

Country

United States

Listings

0 Comments

Share your thoughts

FAQ

What is Soligenix stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange Soligenix stocks are traded under the ticker DOR.

How many employees does Soligenix have?▼

As of September 05, 2026, the company has 14 employees.

In which sector is Soligenix located?▼

Soligenix operates in the Health & Wellness sector.

When did Soligenix complete a stock split?▼

Soligenix has not had any recent stock splits.

Where is Soligenix headquartered?▼

Soligenix is headquartered in PRINCETON, United States.